AAAAAA
Results: 26-46/46
Authors:
Baselga, J
Pfister, D
Cooper, MR
Cohen, R
Burtness, B
Bos, M
D'Andrea, G
Seidman, A
Norton, L
Gunnett, K
Falcey, J
Anderson, V
Waksal, H
Mendelsohn, J
Citation: J. Baselga et al., Phase I studies of anti-epidermal growth factor receptor chimeric antibodyC225 alone and in combination with cisplatin, J CL ONCOL, 18(4), 2000, pp. 904-914
Authors:
Baselga, J
Citation: J. Baselga, New therapeutic agents targeting the epidermal growth factor receptor, J CL ONCOL, 18(21), 2000, pp. 54S-59S
Authors:
Bellmunt, J
Guillem, V
Paz-Ares, L
Gonzalez-Larriba, JL
Carles, J
Batiste-Alentorn, E
Saenz, A
Lopez-Brea, M
Font, A
Nogue, M
Bastus, R
Climent, MA
de la Cruz, JJ
Albanell, J
Banus, JM
Gallardo, E
Diaz-Rubio, E
Cortes-Funes, H
Baselga, J
Citation: J. Bellmunt et al., Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium, J CL ONCOL, 18(18), 2000, pp. 3247-3255
Authors:
Jimenez, M
Gonzalez-Benito, J
Aznar, AJ
Baselga, J
Citation: M. Jimenez et al., Hydrolytic degradation of polysiloxanic coatings on glass fibers, B S ESP CER, 39(4), 2000, pp. 425-430
Authors:
Gonzalez-Benito, J
Aznar, AJ
Macanita, A
Baselga, J
Citation: J. Gonzalez-benito et al., Thermal transitions of polysiloxane coatings onto glass fibers, B S ESP CER, 39(3), 2000, pp. 396-400
Authors:
Baselga, J
Citation: J. Baselga, Clinical trials of single-agent trastuzumab (Herceptin), SEMIN ONCOL, 27(5), 2000, pp. 20-26
Authors:
Baselga, J
Citation: J. Baselga, Current and planned clinical trials with trastuzumab (Herceptin), SEMIN ONCOL, 27(5), 2000, pp. 27-32
Authors:
Albanell, J
Baselga, J
Citation: J. Albanell et J. Baselga, Systemic therapy emergencies, SEMIN ONCOL, 27(3), 2000, pp. 347-361
Authors:
Baselga, J
Averbuch, SD
Citation: J. Baselga et Sd. Averbuch, ZD1839 ('Iressa')(1,2) as an anticancer agent, DRUGS, 60, 2000, pp. 33-40
Authors:
Fernandez-Larrea, J
Merlos-Suarez, A
Urena, JM
Baselga, J
Arribas, J
Citation: J. Fernandez-larrea et al., A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface, MOL CELL, 3(4), 1999, pp. 423-433
Authors:
Albanell, J
Baselga, J
Citation: J. Albanell et J. Baselga, The ErbB receptors as targets for breast cancer therapy, J MAMMARY G, 4(4), 1999, pp. 337-351
Authors:
D'Andrea, G
Fennelly, D
Norton, L
Baselga, J
Gilewski, T
Hudis, C
Moynahan, ME
Raptis, G
Sklarin, N
Surbone, A
Theodoulou, M
Templeton, MA
Yao, TJ
Seidman, AD
Citation: G. D'Andrea et al., Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer, CLIN CANC R, 5(2), 1999, pp. 275-279
Authors:
Gonzalez-Benito, J
Cabanelas, JC
Vigil, MR
Aznar, AJ
Bravo, J
Baselga, J
Citation: J. Gonzalez-benito et al., Pyrene-doped polyorganosiloxane layers over commercial glass fibers, J FLUORESC, 9(1), 1999, pp. 51-57
Authors:
Baselga, J
Citation: J. Baselga, New horizons: gene therapy for cancer, ANTI-CANC D, 10, 1999, pp. S39-S42
Authors:
Gonzalez-Benito, J
Baselga, J
Aznar, AJ
Citation: J. Gonzalez-benito et al., Microstructural and wettability study of surface pretreated glass fibres, J MATER PR, 93, 1999, pp. 129-134
Authors:
Hudis, C
Seidman, A
Baselga, J
Raptis, G
Lebwohl, D
Gilewski, T
Moynahan, M
Sklarin, N
Fennelly, D
Crown, JPA
Surbone, A
Uhlenhopp, M
Riedel, E
Yao, TJ
Norton, L
Citation: C. Hudis et al., Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy, J CL ONCOL, 17(1), 1999, pp. 93-100
Authors:
Baselga, J
Tripathy, D
Mendelsohn, J
Baughman, S
Benz, CC
Dantis, L
Sklarin, NT
Seidman, AD
Hudis, CA
Moore, J
Rosen, PP
Twaddell, T
Henderson, IC
Norton, L
Citation: J. Baselga et al., Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer, SEMIN ONCOL, 26(4), 1999, pp. 78-83
Authors:
Albanell, J
Baselga, J
Citation: J. Albanell et J. Baselga, Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer, DRUGS TODAY, 35(12), 1999, pp. 931-946
Authors:
Urena, JM
Merlos-Suarez, A
Baselga, J
Arribas, J
Citation: Jm. Urena et al., The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-alpha and membrane type matrix metalloprotease (MT1-MMP), J CELL SCI, 112(6), 1999, pp. 773-784
Authors:
Baselga, J
Norton, L
Albanell, J
Kim, YM
Mendelsohn, J
Citation: J. Baselga et al., Recombinant humanized anti-HER2 antibody (Herceptin (TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts (vol 58, pg 2825, 1998), CANCER RES, 59(8), 1999, pp. 2020-2020
Authors:
Codony-Servat, J
Albanell, J
Lopez-Talavera, JC
Arribas, J
Baselga, J
Citation: J. Codony-servat et al., Cleavage of the HER2 ectodomain is a pervanadate-activable process that isinhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells, CANCER RES, 59(6), 1999, pp. 1196-1201